Grace Therapeutics stock analysis
Want to see GRCE full AI Analyst Report?
Grace Therapeutics (GRCE) Stock Price & Analysis
GRCE Stock Chart & Stats
- Day’s Range
- $1.81 - $1.83
- 52-Week Range
- $1.67 - $5.18
- Previous Close
- $1.81
- Volume
- N/A
- Average Volume (3M)
- 103.54K
- Market Cap
- $38.08M
- Enterprise Value
- $21.94M
- Total Cash (Recent Filing)
- $21.31M
- Total Debt (Recent Filing)
- $0
- Price to Earnings (P/E)
- ―
- Beta
- 1.20
- Next Earnings
- Feb 15, 2027 (Est.)
- EPS Estimate
- -0.15
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
An essentially debt-free balance sheet reduces interest obligations and refinancing exposure while preserving flexibility to fund development. This is a durable financial advantage for a development-stage company, although it does not by itself resolve the need to finance ongoing operations.
Proprietary Delivery Platform
A proprietary topical and transdermal platform gives Grace a defined product-development strategy rather than a broad, unfocused research model. If successfully commercialized, improved localized delivery and patient experience could support differentiated pharmaceutical products in dermatology and related areas.
Governance Continuity
Shareholder support for the board, executive compensation and auditor reinforces continuity in oversight and financial reporting. The annual advisory vote on pay also preserves an ongoing mechanism for investor input, supporting stable governance while the company advances its development strategy.
Bears Say
No Revenue And Persistent Losses
No reported revenue and a substantial continuing net loss indicate that the business has not yet reached commercial scale or demonstrated operating profitability. This limits internal funding capacity and leaves future financial performance dependent on successful product development and eventual commercialization.
Ongoing Cash Burn
Persistently negative operating and free cash flow show that current activities consume cash rather than fund themselves. Continued development spending therefore likely requires external financing over time, which can constrain strategic flexibility and expose the company to dilution or financing availability risk.
Shrinking Equity Base
The sharp reduction in equity alongside materially negative returns indicates that accumulated losses are eroding the capital base. Even with minimal debt, continued deterioration could reduce financial resilience and leave fewer internally funded resources available for advancing the company’s pipeline.
GRCE FAQ
What was Grace Therapeutics’s price range in the past 12 months?
What is Grace Therapeutics’s market cap?
When is Grace Therapeutics’s upcoming earnings report date?
How were Grace Therapeutics’s earnings last quarter?
Is Grace Therapeutics overvalued?
Does Grace Therapeutics pay dividends?
What is Grace Therapeutics’s EPS estimate?
How many shares outstanding does Grace Therapeutics have?
What happened to Grace Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Grace Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Grace Therapeutics Stock Smart Score
Company Description
Grace Therapeutics
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Prashant Kohli
- Employees
- 5
- Website
- www.gracetx.com
- Address
- 103 Carnegie Center, Princeton, NJ, 08540, US
Grace Therapeutics (GRCE) Earnings & Revenues
GRCE Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 1 | 6 | 14 |
| Technical Analysis | 1 | 6 | 2 |
| Moving Averages | 0 | 0 | 12 |












